Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma

J Pediatr Hematol Oncol. 2011 Jul;33(5):e176-9. doi: 10.1097/MPH.0b013e3182028fd9.

Abstract

A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates / therapeutic use*
  • Bevacizumab
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary*
  • Carcinoma, Renal Cell / surgery
  • Combined Modality Therapy
  • Everolimus
  • Fatal Outcome
  • Female
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology*
  • Kidney Neoplasms / surgery
  • Nephrectomy
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyridines / therapeutic use*
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use
  • Sorafenib

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates
  • Phenylurea Compounds
  • Protein Kinase Inhibitors
  • Pyridines
  • Niacinamide
  • Bevacizumab
  • Everolimus
  • Sorafenib
  • Sirolimus